Topic: multiple sclerosis
Leerink analysts predict a doubling of competitive intensity in 15 disease areas by 2023, putting a dozen companies at risk.
Sanofi’s Lemtrada is already struggling in a tough multiple sclerosis field, and a new FDA safety warning isn’t going to help matters.
Merck KGaA's EMD Serono wants to know what’s on the minds of multiple sclerosis patients and their loved ones.
Concerns about discounting on Teva's migraine drug Ajovy are high as the company's generics unit and MS blockbuster falter.
Biogen outperformed this quarter, but analysts still worry about competition for Spinraza and an Alzheimer's candidate that hasn't yet proved out.
Roche’s blockbuster cancer trio held their ground so far this year despite biosimilar rivals in the EU, thanks to growth in the U.S. and China.
Sanofi has struggled to rev up multiple sclerosis therapy Lemtrada, but some new long-term data might help it win over doctors and patients.
Teva’s Copaxone has hung on to market share even in the face of oral competitors and generics. But Novartis aims to change that.
Roche's new five-year Ocrevus data could ratchet up the enthusiasm for the drug—and sway more payers to cover it.
Pharma may have Trump administration allies, but across the pond, Health Minister Matt Hancock has attacked, aiming his toughest remarks at Vertex.